Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Sweeney

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Free Radical Biology & Medicine|October 25, 2011
Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-raysNeil C Estabrook, Helen Chin-Sinex, Anthony J Borgmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2018
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket StudyJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
European Urology|October 6, 2018
Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate CancerLorenzo Tosco, Alberto Briganti, Antony Vincent D'amico, et al.
Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.
Radiation Research|December 20, 2007
Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repairMarc S Mendonca, Helen Chin-Sinex, Jaime Gomez-Millan, et al.
Journal of Medical Internet Research|May 3, 2019
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRana McKay, Hannah Mills, Lillian Werner, et al.
Peerj|July 10, 2015
A reproducible approach to high-throughput biological data acquisition and integrationDaniela Börnigen, Yo Sup Moon, Gholamali Rahnavard, et al.
Nanomedicine (London, England)|October 19, 2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticlesPedro M Valencia, Eric M Pridgen, Brian Perea, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2024
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP databasePascal Pommier, Wanling Xie, Praful Ravi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Free Radical Biology & Medicine|October 25, 2011
Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-raysNeil C Estabrook, Helen Chin-Sinex, Anthony J Borgmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2018
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket StudyJohn D Hainsworth, Funda Meric-Bernstam, Charles Swanton, et al.
European Urology|October 6, 2018
Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate CancerLorenzo Tosco, Alberto Briganti, Antony Vincent D'amico, et al.
Investigational New Drugs|May 26, 2010
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)Michael R Harrison, Noah M Hahn, Roberto Pili, et al.
Radiation Research|December 20, 2007
Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repairMarc S Mendonca, Helen Chin-Sinex, Jaime Gomez-Millan, et al.
Journal of Medical Internet Research|May 3, 2019
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRana McKay, Hannah Mills, Lillian Werner, et al.
Peerj|July 10, 2015
A reproducible approach to high-throughput biological data acquisition and integrationDaniela Börnigen, Yo Sup Moon, Gholamali Rahnavard, et al.
Nanomedicine (London, England)|October 19, 2012
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticlesPedro M Valencia, Eric M Pridgen, Brian Perea, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2024
Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP databasePascal Pommier, Wanling Xie, Praful Ravi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancyAlan Sandler, Michael Gordon, Dinesh P De Alwis, et al.
Pageof 9